Acasti Pharma has chosen WuXi Clinical Development to conduct its STRIVE-ON phase 3 safety trial for GTX-104, a novel injectable nimodipine formulation for intravenous infusion (IV) toaddresses high, unmet medical needs for aneurysmal subarachnoid hemorrhage (aSAH).    aSAH is a rare disease that causes bleeding in the space surrounding the brain and is typically caused by leaking and bursting from weak areas in blood vessels on the brain’s surface.   Acasti submitted its phase 3 safety stud...